In vitro measurement of avidity of radioiodinated antibodies

Christopher C. Badger, Kenneth Krohn, Irwin D. Bernstein

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

A determination of the ability of radiolabeled antibodies to bind to their target antigen is an essential step in the initial selection of antibodies for clinical use as well as a quality control measure. In our studies of the 131I-labeled anti-Thy 1.1 antibody treatment of murine lymphoma we have used cell binding assays with a combination of Lineweaver-Burk analysis to determine immunoreactivity and Scatchard analysis to determine antibody avidity. Both assays were systematically influenced by target cell fixation and measurement of avidity was dependent on immunoreactivity. For 131I-labeled anti-Thy 1.1 antibody, avidity was a much more sensitive indicator of iodination damage and predictor of in vivo behavior than was immunoreactivity, while for other antibodies immunoreactivity has been a better indicator of labeling damage. Thus, immunoreactivity and avidity assays are complementary and knowledge of both factors is required for the design of sensitive quality control procedures for radiolabeled antibodies.

Original languageEnglish (US)
Pages (from-to)605-610
Number of pages6
JournalInternational Journal of Radiation Applications and Instrumentation.
Volume14
Issue number6
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Antibody Affinity
Antibodies
Quality Control
Halogenation
Lymphoma
Antigens
In Vitro Techniques
anti-Thy antibody

Cite this

In vitro measurement of avidity of radioiodinated antibodies. / Badger, Christopher C.; Krohn, Kenneth; Bernstein, Irwin D.

In: International Journal of Radiation Applications and Instrumentation., Vol. 14, No. 6, 1987, p. 605-610.

Research output: Contribution to journalArticle

@article{3756c904b8734e18bb922fc4835ae594,
title = "In vitro measurement of avidity of radioiodinated antibodies",
abstract = "A determination of the ability of radiolabeled antibodies to bind to their target antigen is an essential step in the initial selection of antibodies for clinical use as well as a quality control measure. In our studies of the 131I-labeled anti-Thy 1.1 antibody treatment of murine lymphoma we have used cell binding assays with a combination of Lineweaver-Burk analysis to determine immunoreactivity and Scatchard analysis to determine antibody avidity. Both assays were systematically influenced by target cell fixation and measurement of avidity was dependent on immunoreactivity. For 131I-labeled anti-Thy 1.1 antibody, avidity was a much more sensitive indicator of iodination damage and predictor of in vivo behavior than was immunoreactivity, while for other antibodies immunoreactivity has been a better indicator of labeling damage. Thus, immunoreactivity and avidity assays are complementary and knowledge of both factors is required for the design of sensitive quality control procedures for radiolabeled antibodies.",
author = "Badger, {Christopher C.} and Kenneth Krohn and Bernstein, {Irwin D.}",
year = "1987",
doi = "10.1016/0883-2897(87)90033-X",
language = "English (US)",
volume = "14",
pages = "605--610",
journal = "International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - In vitro measurement of avidity of radioiodinated antibodies

AU - Badger, Christopher C.

AU - Krohn, Kenneth

AU - Bernstein, Irwin D.

PY - 1987

Y1 - 1987

N2 - A determination of the ability of radiolabeled antibodies to bind to their target antigen is an essential step in the initial selection of antibodies for clinical use as well as a quality control measure. In our studies of the 131I-labeled anti-Thy 1.1 antibody treatment of murine lymphoma we have used cell binding assays with a combination of Lineweaver-Burk analysis to determine immunoreactivity and Scatchard analysis to determine antibody avidity. Both assays were systematically influenced by target cell fixation and measurement of avidity was dependent on immunoreactivity. For 131I-labeled anti-Thy 1.1 antibody, avidity was a much more sensitive indicator of iodination damage and predictor of in vivo behavior than was immunoreactivity, while for other antibodies immunoreactivity has been a better indicator of labeling damage. Thus, immunoreactivity and avidity assays are complementary and knowledge of both factors is required for the design of sensitive quality control procedures for radiolabeled antibodies.

AB - A determination of the ability of radiolabeled antibodies to bind to their target antigen is an essential step in the initial selection of antibodies for clinical use as well as a quality control measure. In our studies of the 131I-labeled anti-Thy 1.1 antibody treatment of murine lymphoma we have used cell binding assays with a combination of Lineweaver-Burk analysis to determine immunoreactivity and Scatchard analysis to determine antibody avidity. Both assays were systematically influenced by target cell fixation and measurement of avidity was dependent on immunoreactivity. For 131I-labeled anti-Thy 1.1 antibody, avidity was a much more sensitive indicator of iodination damage and predictor of in vivo behavior than was immunoreactivity, while for other antibodies immunoreactivity has been a better indicator of labeling damage. Thus, immunoreactivity and avidity assays are complementary and knowledge of both factors is required for the design of sensitive quality control procedures for radiolabeled antibodies.

UR - http://www.scopus.com/inward/record.url?scp=45949129487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949129487&partnerID=8YFLogxK

U2 - 10.1016/0883-2897(87)90033-X

DO - 10.1016/0883-2897(87)90033-X

M3 - Article

C2 - 3501420

AN - SCOPUS:45949129487

VL - 14

SP - 605

EP - 610

JO - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

JF - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

SN - 0969-8051

IS - 6

ER -